Background and methods for the international trapidil restenosis trial after percutaneous transluminal coronary angioplasty

A Maresta; Marco Balducelli; Spencer B. King; Aldo Maggioni; Roberto Latini; Tiziano Moccetti; Elisabetta Varani; P. Monici Preti

Related publications

Article2002

Prevention of clinical events and restenosis after percutaneous transluminal coronary angioplasty with trapidil: results of the STARC II study

A Maresta, Marco Balducelli, Spencer B. King, Roberto Latini, Tiziano Moccetti, Alessandro Monici-Preti, Elisabetta Varani, Aldo Maggioni

Article1991

Prevention of restenosis after percutaneous transluminal coronary angioplasty: The search for a “magic bullet”

Walter Hermans, Benno J. Rensing, Bradley H. Strauss, Patrick W. Serruys

American Heart Journal

Article1993

Evaluation of Ketanserin in the Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty

Patrick W. Serruys, Werner Klein, Jan G.P. Tijssen, Wolfgang Rutsch, Guy R. Heyndrickx, Håkan Emanuelsson, Sarah W. Ball, O. Decoster, E. Schoeder, Henry Liberman, Edwin Eichhorn, James T. Willerson, H.V. Anderson, Fareed Khaja, R. Wayne Alexander, Donald S. Baim, Rein Melkert, Joop C. van Oene, R. Van Gool

Article1991

Definition of Restenosis after Percutaneous Transluminal Coronary Angioplasty: A Quickly Evolving Concept

Patrick W. Serruys, Benno J. Rensing, Walter Hermans, Kevin J. Beatt

Journal of Interventional Cardiology

Article1996

Fluvastatin for the prevention of restenosis after coronary balloon angioplasty: angiographic and methodological background of the fluvastatin angioplasty restenosis trial.

David P. Foley, Patrick W. Serruys

PubMed